The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1512: A phase II and pilot trial of pembrolizumab in patients with resectable or unresectable desmoplastic melanoma (DM).
 
Kari Lynn Kendra
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
James Moon
No Relationships to Disclose
 
Siwen Hu-Lieskovan
Consulting or Advisory Role - Amgen; Genmab; Merck
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Nektar (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Plexxikon (Inst); Vaccinex (Inst)
 
William Edgar Carson
No Relationships to Disclose
 
Danae Campos
Employment - QTC Management- A Leidos Company
Travel, Accommodations, Expenses - QTC Management- A Leidos Company
 
Alistair Cochran
No Relationships to Disclose
 
Michael Wu
No Relationships to Disclose
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; PACT Pharma; Tango Therapeutics
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis